Mario Gimona,
Head of Manufacturing, GMP Unit,
Paracelsus Medical University Salzburg
Mario Gimona received his PhD in Genetics and Cell Biology in 1990 and spent his postdoctoral period at the Cold Spring Harbor Laboratory in New York. He has led research labs in Austria and Italy and was awarded a Marie Curie Excellent Grant by the European Union in 2004. Since 2012 he heads the GMP stem cell and EV production unit at PMU and leads a team of researchers investigating the potential of MSC-derived EVs and CDVs in regenerative medicine for application in acute spinal cord injury and for the reduction of scar formation following implant-induced injury.
The EVs and the Secretome: Challenges and Obstacles with EV-based Therapeutics Development
Monday, 13 November 2023 at 16:00
Add to Calendar ▼2023-11-13 16:00:002023-11-13 17:00:00Europe/LondonThe EVs and the Secretome: Challenges and Obstacles with EV-based Therapeutics DevelopmentExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Vesicle-based therapy is increasingly being pursued as a safe, cell-free strategy to combat various immunological, musculoskeletal and neurodegenerative diseases. Extracellular vesicle (EV)-enriched preparations obtained from multipotent mesenchymal stromal cells (MSCs) are of particular interest for therapeutic use since they may convey anti-inflammatory, anti-scarring and cyto-protective activities to the recipient cells and tissues. MSCs secrete a variety of bioactive autocrine and paracrine factors including cytokines, chemokines, extracellular matrix proteases, EVs and growth factors. The MSC-derived secretome is thus a complex mixture of proteins, lipids, macromolecular assemblies and vesicular structures, including various types of EVs. The current knowledge on the dynamic structure of vesicular secretome and its interrelated functions is fragmented and the understanding of the nano- and mesoscale properties is limited. The heterogeneity of the vesicular secretome preparations hampers dose finding, the importance of EV uptake and natural tropism remains to be solved, and technologies to better investigate secretome dynamics and corona/halo formation must be developed. Importantly, activities must be initiated that attempt to quantitatively describe one or more biological activities present in/on EVs that are beneficial in elucidating the complex mode-of-action of the vesicular secretome and to assist in the required dose-finding for pre-clinical and clinical application.
Add to Calendar ▼2023-11-13 00:00:002023-11-14 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023Extracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-11-13 16:00:002023-11-13 17:00:00Europe/LondonThe EVs and the Secretome: Challenges and Obstacles with EV-based Therapeutics DevelopmentExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
